Save Product
Product Details
Synonyms
SNCA, NACP, PARK1, alpha-Synuclein
Source
Human Alpha-Synuclein (A53T), Tag Free (ALN-H5116) is expressed from E. coli cells. It contains AA Met 1 - Ala 140 (Accession # P37840-1 (A53T)).
Predicted N-terminus: Met 1
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 14.5 kDa. The protein migrates as 15 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 100 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human Alpha-Synuclein (A53T), Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human Alpha-Synuclein (A53T), Tag Free (Cat. No. ALN-H5116) is more than 90% and the molecular weight of this protein is around 12-18 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human Alpha-Synuclein (A53T), Tag Free (Cat. No. ALN-H5116) at 1 μg/mL (100 μL/well) can bind Anti-Synucelin alpha/beta Monoclonal Antibody with a linear range of 0.1-4 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Synuclein alpha
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
25 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
